Insomnia

JAMA

Volumn 309, Issue 7, 2013, Pages 706-716

  Buysse, Daniel J ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; BUTALBITAL; CHLORAL HYDRATE; CLORAZEPATE; DECONGESTIVE AGENT; DIPHENHYDRAMINE; DOXEPIN; ESCITALOPRAM; ESZOPICLONE; ETHCHLORVYNOL; FLURAZEPAM; GABAPENTIN; HYDROXYZINE; NEUROLEPTIC AGENT; NIFEDIPINE; OXAZEPAM; PLACEBO; RAMELTEON; SECOBARBITAL; STEROID; TEMAZEPAM; TRAZODONE; TRIAZOLAM; UNINDEXED DRUG; ZALEPLON; ZOLPIDEM;

ADULT; AMNESIA; ANXIETY; ATAXIA; BALANCE IMPAIRMENT; BEDTIME DOSAGE; CASE REPORT; CLINICAL FEATURE; COGNITIVE THERAPY; DIZZINESS; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; ENVIRONMENTAL FACTOR; FALLING; FATIGUE; FEMALE; HEALTH CARE COST; HEREDITY; HIP FRACTURE; HUMAN; INSOMNIA; IRRITABILITY; MEDICAL HISTORY; MENTAL DISEASE; MOOD DISORDER; NIGHTMARE; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PATIENT REFERRAL; PHYSICAL EXAMINATION; PHYSIOLOGY; PREVALENCE; PRIAPISM; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RELAXATION TRAINING; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEDATION; SIDE EFFECT; SLEEP PATTERN; SLEEP QUALITY; SLEEP THERAPY; TREATMENT DURATION;

EID: 84874004497     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2013.193     Document Type: Review

References (76)

1. Roth T, Jaeger S, Jin R, Kalsekar A, Stang PE, Kessler RC. Sleep problems, comorbid mental disorders, and role functioning in the National Comorbidity Survey Replication. Biol Psychiatry. 2006;60(12):1364-1371.
2. Ohayon MM. Prevalence and correlates of nonrestorative sleep complaints. Arch Intern Med. 2005;165(1):35-41.
3. Lichstein KL, Durrence HH, Taylor DJ, Bush AJ, Riedel BW. Quantitative criteria for insomnia. Behav Res Ther. 2003;41(4):427-445.
4. Rosa RR, Bonnet MH. Reported chronic insomnia is independent of poor sleep as measured by electroencephalography. Psychosom Med. 2000;62(4):474-482.
5. Edinger JD, Krystal AD. Subtyping primary insomnia: is sleep state misperception a distinct clinical entity? Sleep Med Rev. 2003;7(3):203-214.
6. Riemann D, Spiegelhalder K, Feige B, et al. The hyperarousal model of insomnia: a review of the concept and its evidence. Sleep Med Rev. 2010;14(1):19-31.
7. Nofzinger EA, Buysse DJ, Germain A, Price JC, Miewald JM, Kupfer DJ. Functional neuroimaging evidence for hyperarousal in insomnia. Am J Psychiatry. 2004;161(11):2126-2128.
8. Morin CM, LeBlanc M, Bélanger L, Ivers H, Mérette C, Savard J. Prevalence of insomnia and its treatment in Canada. Can J Psychiatry. 2011;56(9):540-548.
9. Hohagen F, Käppler C, Schramm E, Riemann D, Weyerer S, Berger M. Sleep onset insomnia, sleep maintaining insomnia and insomnia with early morning awakening - temporal stability of subtypes in a longitudinal study on general practice attenders. Sleep. 1994;17(6):551-554.
10. McCrae CS, Lichstein KL. Secondary insomnia: diagnostic challenges and intervention opportunities. Sleep Med Rev. 2001;5(1):47-61.
11. Laugsand LE, Vatten LJ, Platou C, Janszky I. Insomnia and the risk of acute myocardial infarction: a population study. Circulation. 2011;124(19):2073-2081.
12. Baglioni C, Battagliese G, Feige B, et al. Insomnia as a predictor of depression: a meta-analytic evaluation of longitudinal epidemiological studies. J Affect Disord. 2011;135(1-3):10-19.
13. National Institutes of Health. NIH State-of-the-Science Conference Statement on Manifestations and Management of Chronic Insomnia in Adults. Bethesda, MD: National Institutes of Health; 2005.
14. American Academy of Sleep Medicine. The International Classification of Sleep Disorders Steering Committee Second Edition (ICSD-2) Diagnostic and Coding Manual. Chicago, IL: American Academy of Sleep Medicine; 2005.
15. Edinger JD, Wyatt JK, Stepanski EJ, et al. Testing the reliability and validity of DSM-IV-TR and ICSD-2 insomnia diagnoses: results of a multitrait-multimethod analysis. Arch Gen Psychiatry. 2011;68(10):992-1002.
16. Walsh JK, Coulouvrat C, Hajak G, et al. Nighttime insomnia symptoms and perceived health in the America Insomnia Survey (AIS). Sleep. 2011;34(8):997-1011.
17. Roth T, Coulouvrat C, Hajak G, et al. Prevalence and perceived health associated with insomnia based on DSM-IV-TR; International Statistical Classification of Diseases and Related Health Problems, Tenth Revision; and Research Diagnostic Criteria/International Classification of Sleep Disorders, Second Edition criteria: results from the America Insomnia Survey. Biol Psychiatry. 2011;69(6):592-600.
18. Ohayon MM. Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev. 2002;6(2):97-111.
19. Morin CM, Bélanger L, LeBlanc M, et al. The natural history of insomnia: a population-based 3-year longitudinal study. Arch Intern Med. 2009;169(5):447-453.
20. Morphy H, Dunn KM, Lewis M, Boardman HF, Croft PR. Epidemiology of insomnia: a longitudinal study in a UK population. Sleep. 2007;30(3):274-280.
21. Kessler RC, Berglund PA, Coulouvrat C, et al. Insomnia and the performance of US workers: results from the America Insomnia Survey. Sleep. 2011;34(9):1161-1171.
22. Sarsour K, Kalsekar A, Swindle R, Foley K, Walsh JK. The association between insomnia severity and healthcare and productivity costs in a health plan sample. Sleep. 2011;34(4):443-450.
23. Troxel WM, Buysse DJ, Matthews KA, et al. Sleep symptoms predict the development of the metabolic syndrome. Sleep. 2010;33(12):1633-1640.
24. Vgontzas AN, Liao D, Bixler EO, Chrousos GP, Vela-Bueno A. Insomnia with objective short sleep duration is associated with a high risk for hypertension. Sleep. 2009;32(4):491-497.
25. Spielman AJ, Caruso LS, Glovinsky PB. A behavioral perspective on insomnia treatment. Psychiatr Clin North Am. 1987;10(4):541-553.
26. Espie CA, Broomfield NM, MacMahon KM, Macphee LM, Taylor LM. The attention-intention-effort pathway in the development of psychophysiologic insomnia: a theoretical review. Sleep Med Rev. 2006;10(4):215-245.
27. Harvey AG. A cognitive model of insomnia. Behav Res Ther. 2002;40(8):869-893.
28. Schutte-Rodin S, Broch L, Buysse D, Dorsey C, Sateia M. Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med. 2008;4(5):487-504.
29. Carney CE, Buysse DJ, Ancoli-Israel S, et al. The consensus sleep diary: standardizing prospective sleep self-monitoring. Sleep. 2012;35(2):287-302.
30. Vincent N, Lionberg C. Treatment preference and patient satisfaction in chronic insomnia. Sleep. 2001;24(4):411-417.
31. Ohayon MM, Caulet M. Psychotropic medication and insomnia complaints in 2 epidemiological studies. Can J Psychiatry. 1996;41(7):457-464.
32. Buysse DJ, Germain A, Moul DE, et al. Efficacy of brief behavioral treatment for chronic insomnia in older adults. Arch Intern Med. 2011;171(10):887-895.
33. Morin CM, Espie CA. Insomnia: A Clinical Guide to Assessment and Treatment. New York, NY: Kluwer Academic/Plenum Publishers; 2003.
34. Perlis ML, Smith MT, Jungquist C, Posner D. Cognitive Behavioral Treatment of Insomnia: A Session-by-Session Guide. New York, NY: Springer Verlag; 2005.
35. Sateia MJ, Buysse DJ. Insomnia: Diagnosis and Treatment. London, England: Informa Healthcare; 2010.
36. Morin CM, Culbert JP, Schwartz SM. Nonpharmacological interventions for insomnia: a meta-analysis of treatment efficacy. Am J Psychiatry. 1994;151(8):1172-1180.
37. Murtagh DR, Greenwood KM. Identifying effective psychological treatments for insomnia: a meta-analysis. J Consult Clin Psychol. 1995;63(1):79-89.
38. Pallesen S, Nordhus IH, Kvale G. Nonpharmacological interventions for insomnia in older adults: a meta-analysis of treatment efficacy. Psychotherapy. 1998;35(4):472-482.
39. Smith MT, Perlis ML, Park A, et al. Comparative meta-analysis of pharmacotherapy and behavior therapy for persistent insomnia. Am J Psychiatry. 2002;159(1):5-11.
40. Irwin MR, Cole JC, Nicassio PM. Comparative meta-analysis of behavioral interventions for insomnia and their efficacy in middle-aged adults and in older adults 55+ years of age. Health Psychol. 2006;25(1):3-14.
41. Montgomery P, Dennis J. Cognitive behavioural interventions for sleep problems in adults aged 60+. Cochrane Database Syst Rev. 2003;(1):CD003161.
42. van Straten A, Cuijpers P. Self-help therapy for insomnia: a meta-analysis. Sleep Med Rev. 2009;13(1):61-71.
43. Okajima I, Komada Y, Inoue Y. A meta-analysis on the treatment effectiveness of cognitive behavioral therapy for primary insomnia. Sleep Biol Rhythms. 2011;9(1):24-34.
44. Cheng SK, Dizon J. Computerised cognitive behavioural therapy for insomnia: a systematic review and meta-analysis. Psychother Psychosom. 2012;81(4):206-216.
45. Nowell PD, Mazumdar S, Buysse DJ, Dew MA, Reynolds CF III, Kupfer DJ. Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy. JAMA. 1997;278(24):2170-2177.
46. Holbrook AM, Crowther R, Lotter A, Cheng C, King D. Meta-analysis of benzodiazepine use in the treatment of insomnia. CMAJ. 2000;162(2):225-233.
47. Dündar Y, Boland A, Strobl J, et al. Newer hypnotic drugs for the short-term management of insomnia: a systematic review and economic evaluation. Health Technol Assess. 2004;8(24):iii-x, 1-125.
48. Glass J, Lanctôt KL, Herrmann N, Sproule BA, Busto UE. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ. 2005;331(7526):1169.
49. Buscemi N, Vandermeer B, Friesen C, et al. The efficacy and safety of drug treatments for chronic insomnia in adults: a meta-analysis of RCTs. J Gen Intern Med. 2007;22(9):1335-1350.
50. Mitchell MD, Gehrman P, Perlis M, Umscheid CA. Comparative effectiveness of cognitive behavioral therapy for insomnia: a systematic review. BMC Fam Pract. 2012;13(1):40.
51. Carney CE, Edinger JD. Mutimodal cognitive behavior therapy. In: Sateia MJ, Buysse DJ, eds. Insomnia: Diagnosis and Treatment. London, England: Informa Healthcare; 2010:342-351.
52. Morin CM, Bastien C, Guay B, Radouco-Thomas M, Leblanc J, Vallières A. Randomized clinical trial of supervised tapering and cognitive behavior therapy to facilitate benzodiazepine discontinuation in older adults with chronic insomnia. Am J Psychiatry. 2004;161(2):332-342.
53. Morin CM, Vallières A, Guay B, et al. Cognitive behavioral therapy, singly and combined with medication, for persistent insomnia: a randomized controlled trial. JAMA. 2009;301(19):2005-2015.
54. Ritterband LM, Thorndike FP, Gonder-Frederick LA, et al. Efficacy of an Internet-based behavioral intervention for adults with insomnia. Arch Gen Psychiatry. 2009;66(7):692-698.
55. Kripke DF, Langer RD, Kline LE. Hypnotics' association with mortality or cancer: a matched cohort study. BMJ Open. 2012;2(1):e000850.
56. Ozminkowski RJ, Wang S, Walsh JK. The direct and indirect costs of untreated insomnia in adults in the United States. Sleep. 2007;30(3):263-273.
57. Mendelson W. Hypnotic medications: Mechanisms of action and pharmacologic effects. In: Kryger MH, Roth T, Dement WC, eds. Principles and Practices of Sleep Medicine. 5th ed. St Louis, MO: Elsevier; 2011.
58. Charney DS, Mihic SJ, Harris RA. Hypnotics and sedatives. In: Brunton LL, Lazo JS, Parker KL, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 11th ed. New York, NY: McGraw-Hill; 2006:401-427.
59. Krystal AD. A compendium of placebo-controlled trials of the risks/benefits of pharmacological treatments for insomnia: the empirical basis for US clinical practice. Sleep Med Rev. 2009;13(4):265-274.
60. Walsh JK, Krystal AD, Amato DA, et al. Nightly treatment of primary insomnia with eszopiclone for 6 months: effect on sleep, quality of life, and work limitations. Sleep. 2007;30(8):959-968.
61. Krystal AD, Erman M, Zammit GK, Soubrane C, Roth T; ZOLONG Study Group. Long-term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study. Sleep. 2008;31(1):79-90.
62. Ancoli-Israel S, Richardson GS, Mangano RM, Jenkins L, Hall P, Jones WS. Long-term use of sedative hypnotics in older patients with insomnia. Sleep Med. 2005;6(2):107-113.
63. Walsh JK, Roth T. Pharmacologic treatment of insomnia: benzodiazepine receptor agonists. In: Kryger MH, Roth T, Dement WC, eds. Principles and Practices of Sleep Medicine. 5th ed. St Louis, MO: Elsevier; 2011:905-915.
64. Licata SC, Rowlett JK. Abuse and dependence liability of benzodiazepine-type drugs: GABA(A) receptor modulation and beyond. Pharmacol Biochem Behav. 2008;90(1):74-89.
65. Roehrs T, Bonahoom A, Pedrosi B, Rosenthal L, Roth T. Disturbed sleep predicts hypnotic self-administration. Sleep Med. 2002;3(1):61-66.
66. Hajak G, Müller WE, Wittchen HU, Pittrow D, Kirch W. Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data. Addiction. 2003;98(10):1371-1378.
67. Buysse DJ. Clinical pharmacology of other drugs used as hypnotics. In: Kryger MH, Roth T, Dement WC, eds. Principles and Practices of Sleep Medicine. 5th ed. St Louis, MO: Elsevier; 2011:492-509.
68. Krystal AD. Pharmacologic treatment: other medications. In: Kryger MH, Roth T, Dement WC, eds. Principles and Practices of Sleep Medicine. 5th ed. St Louis, MO: Elsevier; 2011:916-930.
69. Roth T, Seiden D, Sainati S, Wang-Weigand S, Zhang J, Zee P. Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Med. 2006;7(4):312-318.
70. Richardson GS, Zee PC, Wang-Weigand S, Rodriguez L, Peng X. Circadian phase-shifting effects of repeated ramelteon administration in healthy adults. J Clin Sleep Med. 2008;4(5):456-461.
71. Krystal AD, Lankford A, Durrence HH, et al. Efficacy and safety of doxepin 3 and 6 mg in a 35-day sleep laboratory trial in adults with chronic primary insomnia. Sleep. 2011;34(10):1433-1442.
72. Roth T, Rogowski R, Hull S, et al. Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in adults with primary insomnia. Sleep. 2007;30(11):1555-1561.
73. Buscemi N, Vandermeer B, Hooton N, et al. The efficacy and safety of exogenous melatonin for primary sleep disorders: a meta-analysis. J Gen Intern Med. 2005;20(12):1151-1158.
74. Taibi DM, Landis CA, Petry H, Vitiello MV. A systematic review of valerian as a sleep aid: safe but not effective. Sleep Med Rev. 2007;11(3):209-230.
75. Glass JR, Sproule BA, Herrmann N, Busto UE. Effects of 2-week treatment with temazepam and diphenhydramine in elderly insomniacs: a randomized, placebo-controlled trial. J Clin Psychopharmacol. 2008;28(2):182-188.
76. Walsh JK, Erman M, Erwin CW, et al. Subjective hypnotic efficacy of trazodone and zolpidem in DSM-III-R primary insomnia. Hum Psychopharmacol. 1998;13(3):191-198.